Stockscreener 앱 받기
6.325
4.10%
-0.265
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
3,350,000 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Vestal Point Capital LP - MarketBeat
Sovereign s Capital Management LLC Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Deutsche Bank AG Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Janus Henderson Group PLC Cuts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Fabry Disease Market: Epidemiology, Therapies, Companies, - openPR.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by D. E. Shaw & Co. Inc. - MarketBeat
Enzyme Replacement Therapy Market Generated Opportunities, - openPR.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Cut by BNP Paribas Financial Markets - MarketBeat
Orbimed Advisors LLC Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Prosight Management LP Invests $8.67 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Northern Trust Corp Has $31.76 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Hudson Bay Capital Management LP Buys 379,800 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Batten Disease Treatment Market Size, Outlook 2031 by Key - openPR.com
Parkman Healthcare Partners LLC Has $7.39 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Balyasny Asset Management L.P. Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Raymond James Financial Inc. Purchases Shares of 13,983 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now? - Insider Monkey
Bayesian Capital Management LP Purchases 54,100 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Schonfeld Strategic Advisors LLC Sells 97,156 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Algert Global LLC - MarketBeat
Marshall Wace LLP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference - GlobeNewswire
Oversold Conditions For Amicus Therapeutics (FOLD) - Nasdaq
Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 - BioWorld MedTech
Pompe Disease Market Expected to Experience Major Growth - openPR.com
Voya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Aquatic Capital Management LLC Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Tower Research Capital LLC TRC - MarketBeat
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo
Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, M - GuruFocus
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, Maintains Buy Rating | FOLD Stock News - GuruFocus
Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News - GuruFocus
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls - TradingView
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Dise - GuruFocus
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News - GuruFocus
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Amicus Therapeutics’ Earnings Call Highlights Growth and Strategic Moves - TipRanks
Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 - GuruFocus
0.76%
2.08%
자본화:
|
볼륨(24시간):